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Background :  Pollen exposure induces local and systemic allergic 
immune responses in sensitized individuals, but also non- sensitized 
individuals are exposed to pollen. The kinetics of symptom expres-
sion under natural pollen exposure has never been systematically 
studied, especially including non- allergic subjects. 
We monitored the humoral immune response under natural pol-
len exposure to potentially uncover nasal biomarkers for in- season 
symptom severity and to identify protective factors. 
Method :  We compared humoral immune response kinetics in a panel 
study on seasonal allergic rhinitis (SAR) and non- allergic (NA) sub-
jects, and tested for cross- sectional and inter- seasonal differences in 
levels of serum and nasal, total and Bet v 1- specific immunoglobulin 
(Ig) isotypes, Ig free light chains, cytokines and chemokines. Non- 
supervised principal component analysis (PCA) was performed for 
all nasal immune variables and single immune variables were corre-
lated with in- season symptom severity by Spearman test. 
Results :  Symptoms followed airborne pollen concentrations in SAR 
subjects with a time lag between 0 and 13 days, depending on the 
pollen type. Out of 7 NA subjects, 4 also exhibited in- season symp-
toms whereas 3 did not. Cumulative symptoms in NA were lower 
than in SAR but followed the pollen exposure with similar kinetics. 
Nasal Eotaxin- 2, MDC and MCP- 1 levels were higher in SAR, IL- 8
higher in NA subjects. PCA and Spearman correlations identified 
nasal IL- 8, IL- 33, and Bet v 1- specific IgG 4  (sIgG 4 ) and sIgE antibodies 
as predictive for seasonal symptom severity. 
Conclusion :  Nasal pollen- specific IgA and IgG isotypes are poten-
tially protective within the humoral compartment. Nasal IL- 8, IL- 33, 
sIgG 4  and sIgE could be predictive biomarkers for pollen- specific 
symptom expression, irrespective of atopy. 
          
                                       
                                                                  
                
                                                                
                                                                      
                                                                    
                                                                       
                                                              
                                                         
                                     
                                                                
                                                                       
                                                                         
                                                                  
                                                                    
                                                                     
                                                                
                                                                 
                                                                    
                                                                    
                                                                  
                                                                   
                                                                 
                                                                  
                                                                     
                                                                    
                                                               
                                                                  
          
                                                                   
                                                                   
                                                                      
                                                                      
                                                                        
                                                                    
                                                              
                                                                    
                                                                    
                                                                     
                                                                   
                                                                   
                                                                     
                                                               
